These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
556 related articles for article (PubMed ID: 19059824)
1. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan. Chen W; Huang SL; Huang CS; Tsai MC; Lai HM; Lui CC; Eng HL; Chang HW; Lee CH; Chuang FR Eur J Dermatol; 2009; 19(1):44-9. PubMed ID: 19059824 [TBL] [Abstract][Full Text] [Related]
2. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006. Kendrick-Jones JC; Voss DM; De Zoysa JR Nephrology (Carlton); 2011 Feb; 16(2):243-8. PubMed ID: 21272139 [TBL] [Abstract][Full Text] [Related]
3. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784 [TBL] [Abstract][Full Text] [Related]
4. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience. Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488 [TBL] [Abstract][Full Text] [Related]
5. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Lim YL; Lee HY; Low SC; Chan LP; Goh NS; Pang SM Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Bryant BJ; Im K; Broome DR Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215 [TBL] [Abstract][Full Text] [Related]
7. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients? Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951 [TBL] [Abstract][Full Text] [Related]
8. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969 [TBL] [Abstract][Full Text] [Related]
10. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Rydahl C; Thomsen HS; Marckmann P Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066 [TBL] [Abstract][Full Text] [Related]
11. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Grobner T; Prischl FC Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001 [TBL] [Abstract][Full Text] [Related]
12. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness. Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720 [TBL] [Abstract][Full Text] [Related]
13. Nephrogenic fibrosing dermopathy: a series in a non-Western population. Panda S; Bandyopadhyay D; Tarafder A J Am Acad Dermatol; 2006 Jan; 54(1):155-9. PubMed ID: 16384776 [TBL] [Abstract][Full Text] [Related]
16. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927 [TBL] [Abstract][Full Text] [Related]
17. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2007 Feb; 56(7):137-41. PubMed ID: 17318112 [TBL] [Abstract][Full Text] [Related]
18. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. Mathur K; Morris S; Deighan C; Green R; Douglas KW J Clin Apher; 2008; 23(4):144-50. PubMed ID: 18633995 [TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis: clinical spectrum of disease. Mayr M; Burkhalter F; Bongartz G J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929 [TBL] [Abstract][Full Text] [Related]